Revised SPC: Libtayo (cemiplimab) 350 mg concentrate for solution for infusion

SPC revised to warn that severe and fatal immune-related adverse reactions, which may involve any organ system, have been observed with cemiplimab, and whilst most of these reactions initially manifest during treatment, they can occur after discontinuation of cemiplimab.


electronic Medicines compendium